Early COVID-19 and protection from Omicron in a highly vaccinated population in Ontario, Canada: a matched prospective cohort study
In our highly vaccinated population, early SARS-CoV-2 infection was associated with a 44% reduction in symptomatic COVID-19 during the first 14 months of Omicron, providing significant protection against re-infection for more than 2 years.
Authors
- Tony Mazzulli (ORCID: https://orcid.org/0000-0002-2682-8792)
- Allison McGeer (ORCID: https://orcid.org/0000-0001-5647-6137)
- Christopher Kandel
- Maria Major (ORCID: https://orcid.org/0000-0003-3719-7225)
- Altynay Shigayeva
- Brenda L. Coleman (ORCID: https://orcid.org/0000-0002-7144-4827)
- Lois Gilbert
- Jelena Vojicic
- Pingping Zhang (ORCID: https://orcid.org/0009-0008-7145-5391)
- Lubna Farooqi
- Samira Mubareka (ORCID: https://orcid.org/0000-0001-5012-2311)
- Jingyan Yang (ORCID: https://orcid.org/0000-0001-5523-649X)
- Wayne L. Gold (ORCID: https://orcid.org/0000-0002-4621-8772)
- Catherine Martin (ORCID: https://orcid.org/0000-0003-2961-4666)
- Anne‐Claude Gingras (ORCID: https://orcid.org/0000-0002-6090-4437)
- Moe H. Kyaw (ORCID: https://orcid.org/0000-0002-0258-6645)
- Zoë Zhong
- John M. McLaughlin
Institutions
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- Pfizer (United States) (US)
- University of Toronto (CA)
- Lunenfeld-Tanenbaum Research Institute (CA)
- Toronto East General Hospital (CA)
- Health Sciences Centre (CA)
- Public Health Ontario (CA)
- Sinai Health System (CA)
- Pfizer (Canada) (CA)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-02-08
- DOI
- https://doi.org/10.1186/s12879-024-10331-1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer